by qfrsolutions | Sep 12, 2016 | News
Source: Horizon Pharma Plc (HZNP.O) said it would buy Raptor Pharmaceutical Corp (RPTP.O) for nearly $800 million to bolster its portfolio of drugs to treat rare diseases and reduce its dependence on the primary care market. The deal will give Horizon drugs used to...
by qfrsolutions | Aug 25, 2016 | News
Source: Celgene ($CELG) has successfully fought off several lawsuits suggesting the success of its blockbuster multiple myeloma meds Revlimid and Thalomid relied on aggressive off-label marketing. A California whistleblower case, however, has moved forward with the...
by qfrsolutions | Aug 25, 2016 | News
Source: FierceBiotech The late-stage skin condition biotech Novan is looking to batter ongoing headwinds and gun for a $60 million public offering. The Durham, NC-based company, which is around a decade old, is working on nitric oxide based therapies for dermatologic...
by qfrsolutions | Aug 15, 2016 | News
Source: Allergan ($AGN) thinks facial injectable Kybella has the potential to one day bank Botox-level sales. And the company is starting up a couple new studies to help it get there. The Dublin drugmaker is initiating trials of the med in bra-line fat and fat around...
by qfrsolutions | Aug 11, 2016 | News
Source: Reuters U.S. prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc (VRX.N) over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales, the Wall Street Journal reported...
by qfrsolutions | Aug 1, 2016 | News
Source: Real Money Valeant Pharmaceuticals’ (VRX) new CEO Joseph Papa may have spoken too soon in his pledge to begin to curb drug prices that had been hiked to controversial levels — especially as the drugmaker’s roughly $31 billion debt package did...
